RxDoctor Payments Data

Colombia Ptacek

Family · West Des Moines, IANPI 1083102933

Payments from drug & device makers

$2,864in general payments, 2019–2025

Across 123 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$403
  • AbbVie$401
  • Johnson & Johnson$361
  • Sanofi$292
  • Ardelyx, Inc.$154
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$141
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,67293%
  • Education$1927%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,864 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$36,745
Medicare patients
260
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$238,773
CreonLipase/Protease/Amylase51$111,426
LinzessLinaclotide65$46,335
IbsrelaTenapanor Hcl18$31,583
ViberziEluxadoline12$19,317
MotegrityPrucalopride Succinate18$14,018
Dexlansoprazole DrDexlansoprazole23$5,133
Omeprazole336$3,979
Lubiprostone18$3,637
Mesalamine ErMesalamine12$3,133
Balsalazide Disodium21$2,304
Pantoprazole Sodium210$1,417
Azathioprine59$1,201
Famotidine218$1,200
Lactulose22$1,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$401$177,078128 claims
Ardelyx, Inc.Ibsrela$154$31,58318 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$139$14,01818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.

Other family in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →